Health Group Expands
Cosmos Health plans Doc Pharma acquisition, enhancing production and adding $6.7M in sales
Anonymous
Cosmos Health (NASDAQ: COSM) has signed a non-binding letter of intent to acquire 100% of Doc Pharma S.A., a Greek GMP-licensed pharmaceutical manufacturer, Stock Titan reported. The deal would add roughly $6.7 million in annual revenue and a 59,000-square-foot production facility to Cosmos Health's growing portfolio.
The announcement carries an unusual wrinkle: Doc Pharma S.A. is managed by the wife of Cosmos Health CEO Greg Siokas, making it a related-party transaction under SEC rules. An independent committee of directors will review the deal, and shareholders must approve it before it closes, according to Barchart.
A Decade-Long Relationship Finally Moves Toward a Deal
Cosmos Health and Doc Pharma S.A. have worked together for years. Cosmos first signed an MOU to buy Doc Pharma back in May 2016, but that agreement expired without a deal. Since then, Cosmos has been a major customer of Doc Pharma, holding a prepaid balance of roughly $3.99 million with the manufacturer as of September 2025, according to SEC filings.
CEO Greg Siokas called this "a defining step in our vision to build a global, diversified, vertically integrated healthcare powerhouse." He added that bringing manufacturing in-house is expected to "expand our production capacity and create lasting value." Siokas himself has bought more than 3.3 million COSM shares in 2025 and 2026.
What Doc Pharma Brings to the Table
Doc Pharma S.A. operates a GMP-licensed plant in Pallini, Attica, Greece. Its facility spans about 59,000 square feet and produces tablets, hard capsules, sachets, suspensions, solutions, and sprays. The company carries an average asset base of roughly $24 million and generates about $3.2 million in gross profit per year, Weekly Voice reported.
For Cosmos, the key benefit is margin capture. Right now, Cosmos pays Doc Pharma to manufacture products it then sells. Bringing that production in-house would let Cosmos keep the manufacturing margin for itself. The company said the deal is expected to be "immediately accretive" — meaning it should add to profits right away.
Related-Party Deal Triggers Strict Oversight Requirements
Because Doc Pharma's managing director is Siokas's wife, the SEC classifies this as a related-party transaction. That triggers several safeguards. An independent board committee must review the deal. The committee will also commission an independent fairness opinion and a full audit of Doc Pharma's financials. A majority of disinterested shareholders must then vote to approve it, Barchart noted.
Critics point to these conflicts as a reason for caution. While Cosmos posted record revenue of $65.3 million in FY2025 — up 20% year-over-year — the company reported a net loss of $21.1 million over the past 12 months. COSM shares traded near $0.2285 at the time of the announcement, down more than 50% year-to-date, and Nasdaq granted the company a 180-day extension through December 7, 2026, to get back above the $1.00 minimum bid price.
Cosmos Eyes $200M Revenue Target With Manufacturing Push
This deal fits a broader strategy. Cosmos has been shifting from a pure drug distributor to a manufacturer and brand owner. It already acquired Cana Laboratories, a 54,000-square-foot facility, and German distributor Docpharm GmbH in 2023. Adding Doc Pharma's plant would further support launches in the U.S. nutraceutical market and a new animal health line targeting a $69 billion global veterinary sector, according to Financial Content.
Management projects revenue of $200.6 million and adjusted EBITDA of $44.2 million by 2029. The company also identified $20 million in non-core assets to sell, with proceeds earmarked for acquisitions and debt reduction. The Doc Pharma deal is a non-binding LOI for now, and there is no guarantee it will close.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
3
Reach
4
Topics
A
AnonymousAuthor
